Loading…
NRXS
Neuraxis, INC
NYSE American· Healthcare· Biotechnology· CUSIP 64134X201
$6.00-0.33%Price as of Aug 29, 18:42 UTC · updated once a day, after the close
Key metrics
- Market cap
- $75.35M
- P/E
- —
- Forward P/E
- —
- P/B
- 11.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.76
- ROE
- -139.76%
- Profit margin
- -144.44%
- Revenue growth
- +115.70%
- Beta
- 1.48
- 52-week high
- $9.33
- 52-week low
- $2.21
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +77.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $4.54 | $2.35 | $2.67 | |
| P/S | 7.2x | 14.2x | 6.3x | 7.2x |
| P/B | — | 14.9x | 8.2x | — |
| EPS | -$0.95 | -$1.22 | -$4.50 | |
| Profit margin | -306.84% | -218.55% | -306.84% | -594.57% |
| ROE | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RNXTRenovoRx, Inc. | $1.67 | — | 8.4x | — | -125.23% | $75.37M |
| LONALeonaBio, Inc. | $7.94 | — | 2.2x | — | -431.39% | $74.81M |
| ELTXElicio Therapeutics, Inc. | $2.84 | — | 7.8x | — | -774.56% | $74.64M |
| OSTXOS Therapies Inc | $1.64 |
About the company
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
- 24
- Carmel, United States
Company description provided by Yahoo Finance.